Connect with us

Policy

Discussing Alberta’s move to regulate psychedelic therapy

James Bunn, Project Delivery Manager at Canadian non-profit TheraPsil, speaks to Psychedelic Health about Alberta’s new regulations.

Published

on

A brief history of psychedelics

Will Alberta’s new regulatory framework for the delivery of psychedelic therapies pave the way for their integration into the healthcare system, or will it create a barrier to access for patients?

Alberta will be regulating the delivery of psychedelic-assisted therapies to ensure the safety of patients.  

The bill proposes that, with certain exceptions, clinics offering psychedelic-assisted treatment must be licensed and have the medical oversight of a psychiatrist, and patients undergoing psychedelic drug treatment must be monitored by qualified health professionals.

The change will only apply to licensed medicines which, in Canada, is currently only ketamine, with substances such as MDMA and psilocybin being delivered as unlicensed medicines under Canada’s Special Access Programme.

Limiting patient access?

The development in Alberta has been largely welcomed, but Project Delivery Manager at non-profit TheraPsil, a coalition of professionals dedicated to providing access to psilocybin therapy for patients in Canada with a palliative diagnosis, James Bunn, highlights that reservations remain regarding the lack of patient consultation over the process and the challenges that some of the changes may create for patients. 

“This development is about laying the groundwork for the method in which psychedelic-assisted psychotherapy is going to be delivered going forward as drugs become regulated in Alberta,” says Bunn. 

“There are two things that people within this industry think are terrible about this change.

“The first being the need for a psychiatrist throughout this process. Lots of people believe that to deliver this sort of therapy, you don’t really need a psychiatrist to be present and if anything, they know less than the psychotherapists. It’s just a different kind of modality.”

See also  Calls for psilocybin access rights for UK cluster headache sufferers

Bunn highlights that the requirement to have a therapist present during the delivery of the care will only rack up prices for patients. In the short term, with the changes currently only applying to ketamine, this would pose a barrier to patient access to ketamine therapy in Alberta.

In the long term, this could have an impact on patient access to psychedelic therapies in Alberta as regulation around therapies such as MDMA and psilocybin evolve.

“It does mean that those in Alberta will have to have a psychiatrist on board throughout the process, which is inevitably going to rack the prices up and price some people out. Whereas actually, you could do it with a registered nurse that’s gone through psychedelic-assisted psychotherapy training. 

“And although the regulation states you need a psychiatrist there, they don’t say that psychiatrist needs to be trained to deliver this type of therapy.

“However, I also understand that in order for government agencies and regulators to feel comfortable with this in the first place, you need to take the most conservative approach.”

For feedback on the framework, the government did not consult with patients or patient bodies, notes Bunn.

“The other thing that I think the psychedelic industry will lament by this decision is the consultation process that happened to come to these decisions. This one does seem to have happened a lot behind closed doors. 

“The consultation should really take into account patient views on the matter. It does feel like a lost opportunity to get consulted those that do the therapist training in Canada and do the clinical trials which are approved. I wish they had opened this out to asking for patient views on this and also those that facilitate patient access.”

See also  Canada's amendment allowing patients access to psychedelics welcomed

Change is coming

Bunn emphasises that, while there may be issues that need ironing out, the development is a win for psychedelic-assisted therapies – with the move symbolising a coming change.

“This is a symbolic move of the Canadian province,” said Bunn. “It is saying – let’s take a chance on regulating psychedelic therapy. Firstly, this indicates that Alberta’s government is aware that change is coming – that something is going to happen soon and that there is a need to do this. 

“Otherwise, they would have just said that these are the rules for regulating ketamine, but they said these are the rules for regulating psychedelic therapy. I think that’s a really huge win.

“I’m really pleased that this is moving forward. It’s a great sign – Canada is showing really good promise of progressive policies.”

Bunn says the best way for progression to happen now would be federalised regulation on psychedelic-assisted therapies, rather than on a state-by-state basis.

“Advocacy groups need to be involved, whether that’s charities or non-profits that have been operating in the space for years,” says Bunn. “Key academics need to be involved as well as those that have been delivering them as a clinical investigator for a clinical trial of some kind.

“A process of how prescriptions are delivered to patients needs to be worked out, and whether it’s included on local insurance, for example. I would like at least to see a want from the government to get as many views on this as possible because there are a lot of people that would love to talk about this. 

See also  Italian campaign on psychotropic substances has signatures verified

“Overall, this is a great win. It’s just a hard one to swallow sometimes.”

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Policy

Now is the time for psychedelic access, says campaigner

Published

on

Now is the time for psychedelic access, says campaigner

Activists in Oakland recently filed a ballot put forward by Dave Hodges seeking to legalise safe and legal access to psychedelics for therapeutic uses. 

In the face of critics, Hodges has said now is the time for safe access to psychedelics.

The Psychedelic Wellness & Healing Initiative would enable the sale, possession and use of psychedelics for therapeutic purposes if passed. Psychedelics that would be allowed under the ballot include Psilocybin, MDMA, DMT, and Mescaline.

If passed, the initiative would give doctors and mental health specialists the right to recommend psychedelics to ease the debilitating symptoms of a range of problems, including obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), depression, anxiety, addiction, suicidality and traumatic brain injury (TBI), among others.

Hodges has said: “Now is the time for safe, controlled medical access for patients in need. The way to solve the problem is not by continuing to ignore it.” 

Hodges’ solution is to create a structure for use that includes proper dosages and access to experts who can help users benefit from appropriate treatment.

The updated initiative language emphasises safety, and gives doctors and mental health specialists the right to recommend psychedelics to ease the debilitating symptoms of a range of conditions.

Research by the University of Michigan and Columbia University shows non-LSD hallucinogenic use on the rise and Hodges has stated that increase means that the initiative providing guidelines for use is needed more than ever. 

Hodges said he hopes Californians will read the initiative, share their thoughts about it over the holiday week and offer feedback via the initiative website, PW4CA.com, by 27 November, 2023, the deadline for modifications.

See also  EU bodies provide perspective on regulation of psychedelics

“Now is the time to provide medical and therapeutic access to psychedelics,” Hodges said. “The way to do this is through the initiative.”

Continue Reading

Policy

Transform Drugs releases groundbreaking book: How to regulate psychedelics

Published

on

Transform Drugs releases book: How to regulate psychedelics

UK charity Transform Drug Policy Foundation has published a new book ‘How to Regulate Psychedelics: A Practical Guide’ that sets out how psychedelics can be legalised and regulated for non-medical adult use.

While an increasing amount of research is pointing to the potentially beneficial effects of psychedelic treatment on mental health conditions, many people across the globe are using psychedelics outside of the clinical setting.

The book includes a set of proposals for post-prohibition policies, covering psychedelics including psilocybin, LSD, DMT and Mescaline. 

Previously, Transform’s guides on regulating stimulants and cannabis have been used to advise governments around the world on drug policy. This book seeks to inform the debates on psychedelic drug reforms taking place across the world.

Co-author and Public Affairs and Policy Manager at Transform Drug Policy Foundation, Ester Kincová, stated: “Despite psychedelic drugs being illegal, their non-medical use within society has been steadily increasing. 

“Punitive enforcement has not decreased use or eliminated supply, but it has made use more unsafe. 

“Legalising and regulating psychedelics is a pragmatic move to reduce harm. This is no longer a theoretical debate, states in the US are already recognising the need and  making moves to regulate for non-medical adult use.”

Scientific Chair of Drug Science, Professor David Nutt, added: “Once again Transform have come up with a well thought out and practical plan for the regulation of another group of currently illegal drugs – in this case psychedelics. 

“Their ideas would be both easy to implement and to engage with and will, if adopted, radically enhance the safe use of these remarkable agents.”

See also  Australia reschedules psilocybin and MDMA

Proposals for regulation

The book includes a four-tiered regulation model “that attempts to manage the variety of psychedelic preparations and the different ways in which they are used”.

These include:

  • Private use, home cultivation, foraging and not-for-profit sharing.
  • Membership-based non-for-profit associations for plant-based products.
  • Licensed production and retail adaptable to different products and environments
  • Regulated commercial guided or supervised use

Additionally, a decriminalisation model is proposed which suggests that possession for personal use should no longer be an offence of any kind or be subject to any sanctions; Drugs for personal use should not be confiscated; cultivation of small amounts of plant-based drugs for personal use should be decriminalised, among other suggestions.

The book also includes topics such as embedding social justice, equity and human rights into policy design, how to think about psychedelics regulation, why regulate psychedelics and why now, and psychedelics and the UN drug treaties.

To read the book, please visit transformdrugs.org/.

Continue Reading

Policy

Oakland ballot seeks to legalise medical psychedelics

Published

on

Oakland ballot seeks to legalise medical psychedelics

Activists in Oakland have filed a ballot that seeks to legalise safe and legal access to psychedelics for therapeutic uses. 

The Psychedelic Wellness & Healing Initiative would enable the sale, possession and use of psychedelics for therapeutic purposes if passed. Psychedelics that would be allowed under the ballot include Psilocybin, MDMA, DMT, and Mescaline.

If passed, the initiative would give doctors and mental health specialists the right to recommend psychedelics to ease the debilitating symptoms of a range of problems, including obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), depression, anxiety, addiction, suicidality and traumatic brain injury (TBI), among others.

See also  Australia reschedules psilocybin and MDMA

Additionally, it would create a statewide framework for regulating the possession, use, cultivation and production of substances for medical and therapeutic use.

The initiative has been introduced by proponent and founder of the Oakland-based Church of Ambrosia, Dave Hodges, to the California Attorney General’s office for the 2024 ballot, and will need 546,651 valid signatures to qualify.

See also  CDPRG discusses the UK's Reschedule Psilocybin campaign

The filing follows California Governor Gavin Newsom’s recent veto of Senate Bill 58, the bill that sought to decriminalise the use of certain psychedelic drugs. 

Hodges emphasised that SB58 would have been a step forward, but that it had major flaws concerning its lack of provisions to ensure access, public safety and quality control. That veto, Hodges said, compelled him to move quickly on the initiative filing.

When the California Attorney General certifies the initiative for circulation, backers will have about four and a half months to gather the required signatures for ballot placement. 

Signature collecting will begin in early December.

Continue Reading

Trending